Investing.com -- Recursion Pharmaceuticals (NASDAQ:RXRX) stock tumbled 12% Wednesday morning after regulatory filings revealed that NVIDIA (NASDAQ:NVDA) had completely divested its stake in the ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Andres Almiray, a serial open-source ...

Generative AI is infiltrating everything you do online, including how you find information. If you're bored with traditional search, check out the top AI search engines we've tried. I’ve been writing ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Nearly 300 Burmese pythons were removed during a record-setting Florida Python Challenge this year, state wildlife officials said. The 10-day competition that ran from July 11-20 resulted in a record ...

Measuring binary star systems' basic properties has proved exceedingly difficult. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Breaking space ...

Jon covers artificial intelligence. He previously led CNET's home energy and utilities category, with a focus on energy-saving advice, thermostats, and heating and cooling. Jon has more than a decade ...

Andrej Prša receives funding from the National Aeronautics and Space Administration. Stars are the fundamental building blocks of our universe. Most stars host planets, like our Sun hosts our solar ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Recursion said today it is eliminating approximately 20% of its workforce—about 160 jobs—in a restructuring the AI-based drug developer said reflects both its recently-pruned pipeline and the ...